Definitive Healthcare (DH) Research & Development (2020 - 2026)

Definitive Healthcare (DH) has reported Research & Development for 7 consecutive years, with $19.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 6.4% year-over-year to $19.2 million; the trailing twelve-month figure through Jun 2026 stood at $79.3 million (down 2.91% YoY), and the FY2025 full-year result was $81.6 million, down 2.59% from the prior year.
• Research & Development retreated to $19.2 million in Q2 2026 per DH's latest filing, from $19.6 million in the prior quarter.
• Across five years, Research & Development topped out at $24.7 million in Q2 2023 and bottomed at $19.2 million in Q2 2026.
• Historically, Research & Development has averaged $21.6 million across 5 years, with a median of $21.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 83.06% in 2022, then dropped 13.7% in 2024.
• Over 5 years, Research & Development stood at $23.5 million in 2022, then climbed by 0.35% to $23.6 million in 2023, then declined by 13.7% to $20.4 million in 2024, then dropped by 1.16% to $20.1 million in 2025, then fell by 4.85% to $19.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $19.2 million, $19.6 million, and $20.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.